Clinical Trial Update: Ritonavir-Boosted GS-9137 vs. Ritonavir-Boosted Protease Inhibitor(s) in Combination With Background ART. [Phase 2]

View source ↗

Summary

Phase 2 trial comparing ritonavir-boosted GS-9137 (elvitegravir) against ritonavir-boosted protease inhibitors, both with background ART, in HIV infection; the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Ritonavir (Ritonavir)
• elvitegravir (elvitegravir)

Snippet

Sponsor: Gilead Sciences | Conditions: HIV, HIV-1 | Phase 2 | Status: COMPLETED